Esophagectomy for adenocarcinoma in patients 45 years of age and younger

被引:19
作者
Bolton, JS
Wu, TT
Yeo, CJ
Cameron, JL
Heitmiller, RF
机构
[1] Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
关键词
esophageal neoplasm; Barrett's; adenocarcinoma;
D O I
10.1016/S1091-255X(01)80104-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Esophageal adenocarcinoma in patients 45 years of age or younger is uncommon. We reviewed our experience with die surgical management of these patients to determine their clinical characteristics, pathologic findings, and treatment results. Thirty-two patients were identified through our surgical pathology, database, and their medical records were reviewed to determine clinical characteristics, treatment, treatment-associated mortality, tumor staging, presence of Barrett's mucosa, and survival. In our series, patients were white (100%) males (96.9%) with a history of reflux (56.3%), cigarette smoking (40.6%), and alcohol consumption (59.4%), who presented with progressive solid food dysphagia (78.1%). A prior diagnosis of Barrett's mucosa or use of antireflux medications was noted in five patients each (15.6%). There were no operative deaths. Actuarial survival was 81.1% (95% confidence interval [CI] 66.1 to 96.2) at 12 months, 68.5% (95% CI 49.5 to 87.5) at 24 months, and 56.9% (95% CI 34.6 to 79.1) at 60 months. Our findings show that patients with esophageal adenocarcinoma 45 years of age or younger have similar clinical findings to those reported in other large series where the median age is in the sixth or seventh decade of life, supporting a uniform theory of tumor pathogenesis. Esophagectomy may be performed with low mortality, and survival is reasonable for early-stage disease. Young patients with Barrett's esophagus are not immune from the development of adenocarcinoma and need to be screened accordingly.
引用
收藏
页码:620 / 625
页数:6
相关论文
共 24 条
[11]   Comparison of prevalence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinoma [J].
Heitmiller, RF ;
Sharma, RR .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 112 (01) :130-136
[12]  
HEITMILLER RF, 1995, CURRENT SURG THERAPY, P45
[13]   Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma [J].
Lagergren, J ;
Bergström, R ;
Lindgren, A ;
Nyrén, O .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (11) :825-831
[14]  
MENKEPLUYMERS MBE, 1993, CANCER, V72, P1155, DOI 10.1002/1097-0142(19930815)72:4<1155::AID-CNCR2820720404>3.0.CO
[15]  
2-C
[16]   ONLY PATIENTS WITH DYSPLASIA PROGRESS TO ADENOCARCINOMA IN BARRETT-ESOPHAGUS [J].
MIROS, M ;
KERLIN, P ;
WALKER, N .
GUT, 1991, 32 (12) :1441-1446
[17]   MESOTHELIOMA MORTALITY IN ASBESTOS WORKERS - IMPLICATIONS FOR MODELS OF CARCINOGENESIS AND RISK ASSESSMENT [J].
PETO, J ;
SEIDMAN, H ;
SELIKOFF, IJ .
BRITISH JOURNAL OF CANCER, 1982, 45 (01) :124-135
[18]  
REID BJ, 1992, GASTROENTEROLOGY, V102, P1212
[19]   Adenocarcinoma of the esophagus with and without Barrett mucosa [J].
Sabel, MS ;
Pastore, K ;
Toon, H ;
Smith, JL .
ARCHIVES OF SURGERY, 2000, 135 (07) :831-835
[20]  
Salazar J D, 1998, Dis Esophagus, V11, P168